<DOC>
	<DOCNO>NCT02876419</DOCNO>
	<brief_summary>The REP 301 treatment protocol involve treatment patient chronic hepatitis B / hepatitis D co-infection two agent : REP 2139-Ca pegylated interferon ( peg-IFN ) . In protocol , similar reduction/clearance serum HBsAg improve response immunotherapy observe addition clearance serum HDV RNA . The REP 301 protocol design include 24 week follow-up period treatment , however give strong antiviral response HBV HDV infection patient , important extend follow-up period patient monitor long period treatment safety efficacy combine REP 2139-Ca / peg-IFN treatment patient REP 301 protocol .</brief_summary>
	<brief_title>A Long Term Follow-up Study Patients From REP 301 Protocol</brief_title>
	<detailed_description>The REP 301-LTF long-term follow-up , non-blinded study patient REP 301 protocol . In study , eligible patient REP 301 protocol followup evaluation extend additional 3 year , consist 6 visit schedule every 6 month follow last follow-up visit schedule REP 301 protocol . During visit physical examination documentation symptom , experience conduct well blood test safety virology describe . This study examine long term safety effect patient complete treatment exposure REP 301 trial ( REP 2139-Ca therapy 30 week PEG-IFN take 48 week 15 week overlap combination ) duration suppression serum HBV HDV viremia observe REP 301 protocol . This require subject complete antiviral treatment REP 301 protocol immediately transition antiviral treatment unless necessary . The total duration study subject 3 year .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Hepatitis D</mesh_term>
	<mesh_term>Hepatitis D , Chronic</mesh_term>
	<criteria>1 . Signed write informed consent . 1 . Any patient enrol REP 301 protocol successfully complete treatment followup visit REP 301 protocol 2 . A history alcohol abuse within last year 3 . The use illicit drug within past two year . 4 . Inability provide inform consent . 5 . Inability unwillingness provide blood sample .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>nucleic acid polymer REP 2139 HBsAg hepatitis B hepatitis D</keyword>
</DOC>